added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to Outperform from Perform, citing a favorable valuation setup ahead of a mid-stage trial readout for its eczema ...

Oppenheimer downgraded Arvinas (ARVN ... of investors polled in a recent survey said they wanted to see the trial hit on the Intention-to-Treat endpoint and argues that without an ITT win it ...

Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to ...

Robert Pattinson is reportedly being eyed for a role in Dune 3, aka Dune: Messiah. The third and final instalment in Denis ...

Discover DURECT's Q4 2024 earnings insights, progress on larsucosterol's Phase 3 trial for alcohol-associated hepatitis, and strategies to secure funding.

On Tuesday, Oppenheimer reaffirmed its positive stance on Kala Pharmaceuticals (NASDAQ ... The company is making progress with its Phase 2b trial for persistent corneal epithelial defect (PCED), ...